Market open

Roivant Sciences/ROIV

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Roivant Sciences

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Ticker

ROIV
Trading on

Industry

Biotechnology

Employees

908

Roivant Sciences Metrics

BasicAdvanced
$8.8B
Market cap
2.09
P/E ratio
$5.65
EPS
1.24
Beta
-
Dividend rate
$8.8B
1.24
$12.44
$8.25
8.3M
27.908
27.407
6.065
6.43
-26.65%
-15.03%
127.72%
2.095
58.143
1.61
1.64
-12.962
101.44%
-524.99%
74.19%
67.52%

What the Analysts think about Roivant Sciences

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Roivant Sciences stock.

Roivant Sciences Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Roivant Sciences Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy ROIV

$

Sign up or log in to buy
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Roivant Sciences stock?

Roivant Sciences (ROIV) has a market cap of $8.8B as of October 15, 2024.

What is the P/E ratio for Roivant Sciences stock?

The price to earnings (P/E) ratio for Roivant Sciences (ROIV) stock is 2.09 as of October 15, 2024.

Does Roivant Sciences stock pay dividends?

No, Roivant Sciences (ROIV) stock does not pay dividends to its shareholders as of October 15, 2024.

When is the next Roivant Sciences dividend payment date?

Roivant Sciences (ROIV) stock does not pay dividends to its shareholders.

What is the beta indicator for Roivant Sciences?

Roivant Sciences (ROIV) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.